Referência:

POCI-01-0145-FEDER-028159

PTDC/EMD-EMD/28159/2017

PI: Vanessa Cardoso

CO-PI: Paulo Coutinho

Resumo/Summary:

In hematologic malignancies (HM), such as leukemia and lymphomas, uncontrolled growth of abnormal neoplastic cells in the bone marrow (BM) interrupts normal blood development. The recognition of the diseases heterogeneity demonstrates the need for specialized care. The vision of MicroTreat is to develop a 3D in vitro cell culture bioreactor based on microfluidic technology, in which patient’s BM cells can be cultured in an environment mimicking the biological niche. This approach along with the development of biocompatible microspheres coated with specific molecules will allow researchers and clinicians to identify the key components of BM that are essential for HM progression, to test existing anti-neoplastic drugs and to develop new therapeutic agents. The use of this innovative platform with drug screening purposes could lead to a European expenditure reduction of around 30 000 million euros due to non-effective treatments that have in addition adverse secondary effects in patients.

Palavras chave:

Hematological malignancies

bone marrow

microfluidic

bioreactor

microspheres

biomimetic

therapeutic

Parceiros:

  • UNIVERSIDADE DO MINHO
  • INL (LABORATÓRIO IBÉRICO INTERNACIONAL DE NANOECNOLOGIA)

Orçamento Global: 225 103, 00€

Orçamento UMinho: 218 603,00 €

-

Apoio Financeiro UM

FEDER: 185 812, 55€

OE: 32 790, 45€

Data início: 01/07/2018

Data Fim: 30/06/2021

 

Financiamento:

FEDER, OE

fctcompte portugal 2020